Meeting Microsite
Example Advisory Board Meeting
Date: October 22, 2026 | Time: 8PM
Format: In-person
Location: Toronto, ON
2025-04-01 21:48:45Format: In-person
Location: Toronto, ON
Agenda
|
Time |
Agenda Item |
Facilitator |
|
6:00 – 6:05 pm |
Welcome & Introductions |
Darren Holt & Dr. Arjun Patel |
|
6:10 – 6:25 pm |
Introduction to Novadyne |
Darren Holt |
|
6:25 – 6:35 pm |
Seeking Understanding and Perceptions Regarding GlucoFlow Patch 0.3% Formulation Properties |
Dr. Arjun Patel & Darren Holt |
|
6:35 – 7:15 pm |
Obtaining Real-World Perspectives: GlucoFlow Patch 0.3% DIAB Clinical Trial Discussions |
Dr. Arjun Patel |
|
Break (15 mins) |
||
|
7:30 – 7:45 pm |
Gathering Insights on Clinical Impact of GlucoFlow Patch DIAB Long-Term Data |
Dr. Arjun Patel |
|
7:45 – 8:30 pm |
Feedback on Product Monograph for GLUCORE™ |
Dr. Emily Ross |
|
8:30 – 9:00 pm |
Share Back & Closing |
Darren Holt |
Pre-work
The Novadyne Diabetes Virtual Western Medical Regional Advisory Board meeting was held virtually on Tuesday, October 2nd, 2026 from 6:00–9:00 pm ET. The advisors consisted of endocrinologists from Alberta, Manitoba, and Saskatchewan. Prior to the meeting, the advisors received a sample of GlucoFlow Technology transdermal patch used in the Novadyne (ND-151) clinical trials, completed a pre-meeting survey, and reviewed the following references:
Smith JM, Doe AL, Rivera P, et al. Effect of GlucoFlow Patch vs Placebo Patch on Glycemic Control in Type 2 Diabetes: The DIAB-1 and DIAB-2 Randomized Clinical Trials. Diabetes Care. 2022; 45(11):1073–1084.
Doe M, Johnson L, Patel S, et al. Durability of Efficacy and Safety of GlucoFlow Patch 0.3% in Adults With Type 2 Diabetes From a 52-Week, Phase 2 Open-Label Safety Trial. Presented: Winter Endocrinology Conference; January 13–18, 2023; Kohala Coast, HI, USA.